NIK expression in HL patient biopsies in the neoplastic cells (RS cells and LP cells)
| Diagnosis . | No. of cases . | Score 3+ . | Score 2+ . | Score 1+ . | 0 . |
|---|---|---|---|---|---|
| cHL* | 31 | 9 | 8 | 13 | 1 |
| Subtype MC | 9 | 3 | 2 | 4 | 0 |
| Subtype NS | 14 | 2 | 3 | 8 | 1 |
| Subtype LR | 4 | 1 | 3 | 0 | 0 |
| NOS | 4 | 3 | 0 | 1 | 0 |
| NLPHL† | 19 | 9 | 7 | 3 | 0 |
| Total | 50 | 18 | 15 | 16 | 1 |
| Diagnosis . | No. of cases . | Score 3+ . | Score 2+ . | Score 1+ . | 0 . |
|---|---|---|---|---|---|
| cHL* | 31 | 9 | 8 | 13 | 1 |
| Subtype MC | 9 | 3 | 2 | 4 | 0 |
| Subtype NS | 14 | 2 | 3 | 8 | 1 |
| Subtype LR | 4 | 1 | 3 | 0 | 0 |
| NOS | 4 | 3 | 0 | 1 | 0 |
| NLPHL† | 19 | 9 | 7 | 3 | 0 |
| Total | 50 | 18 | 15 | 16 | 1 |
A total of 55% of the cHL RS cells showed NIK positivity, and the positivity shows no association with cHL subtypes, whereas 84% of NLPHL LP cells were NIK positive.
LP indicates lymphocyte predominant; MC, mixed cellularity; NS, nodular sclerosis; LR, lymphocyte rich; and NOS, not otherwise specified.
≥ 2+ indicates 17 of 31 (55%).
≥ 2+ indicates 16 of 19 (84%); and ≥ 1+, NIK expression in both cHL and NLPHL: 49 of 50 (98%).